ProfileGDS5678 / 1453128_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 79% 74% 85% 76% 76% 78% 77% 75% 73% 74% 78% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1114376
GSM967853U87-EV human glioblastoma xenograft - Control 25.0121475
GSM967854U87-EV human glioblastoma xenograft - Control 35.5019179
GSM967855U87-EV human glioblastoma xenograft - Control 44.9045374
GSM967856U87-EV human glioblastoma xenograft - Control 56.3932285
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9354176
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0583876
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4168378
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1845277
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9621975
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7625473
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.900174
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3422778
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8058174